Hippo/YAP Signaling Pathway: A Promising Therapeutic Target in Bone Paediatric Cancers?
Osteosarcoma and Ewing sarcoma are the most prevalent bone pediatric tumors. Despite intensive basic and medical research studies to discover new therapeutics and to improve current treatments, almost 40% of osteosarcoma and Ewing sarcoma patients succumb to the disease. Patients with poor prognosis...
Main Authors: | Sarah Morice, Geoffroy Danieau, Françoise Rédini, Bénédicte Brounais-Le-Royer, Franck Verrecchia |
---|---|
Format: | Article |
Language: | English |
Published: |
MDPI AG
2020-03-01
|
Series: | Cancers |
Subjects: | |
Online Access: | https://www.mdpi.com/2072-6694/12/3/645 |
Similar Items
-
The YAP/TEAD Axis as a New Therapeutic Target in Osteosarcoma: Effect of Verteporfin and CA3 on Primary Tumor Growth
by: Sarah Morice, et al.
Published: (2020-12-01) -
The YAP/TAZ Pathway in Osteogenesis and Bone Sarcoma Pathogenesis
by: Heinrich Kovar, et al.
Published: (2020-04-01) -
YAP and the Hippo pathway in pediatric cancer
by: Atif A. Ahmed, et al.
Published: (2017-05-01) -
SHH Signaling Pathway Drives Pediatric Bone Sarcoma Progression
by: Frédéric Lézot, et al.
Published: (2020-02-01) -
Activating the Hippo pathway by nevadensin overcomes Yap-drived resistance to sorafenib in hepatocellular carcinoma
by: Hewen Shi, et al.
Published: (2023-05-01)